SCHEMBL4723158

SCHEMBL4723158

CCCCNc1[c]nnnc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
BCHE P06276 1/20 0.34
TRPC3 Q13507 1/20 0.34
TRPC4 Q9UBN4 1/20 0.34
TRPC5 Q9UL62 1/20 0.34
TLR8 Q9NR97 4/20 0.33
HCAR3 P49019 1/20 0.33
KDM6B O15054 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
ACP1 P24666 1/20 0.32
ALDH1A1 P00352 2/20 0.32
APAF1 O14727 1/20 0.32
KCNH3 Q9ULD8 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
RAB9A P51151 2/20 0.31
TOP2A P11388 1/20 0.31
ELANE P08246 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723574 0.89 ALDH1A1 (0.30) HCAR3ALDH1A1
SCHEMBL4721503 0.75 TLR8 (0.39) KDM4ENPSR1L3MBTL1BCHETRPC3
SCHEMBL17103462 0.68 HRH3 (0.33) KDM4ENPSR1L3MBTL1ALDH1A1RAB9A
SCHEMBL4924798 0.66 LTA4H (0.35) KDM4EL3MBTL1TLR8ALDH1A1SMN1; SMN2
SCHEMBL4720728 0.66 TLR8 (0.33) KDM4ENPSR1L3MBTL1BCHETRPC3
SCHEMBL5103836 0.66 BCHE (0.35) KDM4ENPSR1L3MBTL1BCHETRPC3
SCHEMBL4766998 0.64 LMNA (0.32) SMN1; SMN2ELANELMNAUTS2R
SCHEMBL4721365 0.64 TLR8 (0.40) KDM4ENPSR1L3MBTL1TLR8
SCHEMBL4720427 0.64 NPC1 (0.41) KDM4ENPSR1L3MBTL1BCHETRPC3
SCHEMBL4723660 0.63 TLR8 (0.37) KDM4ENPSR1L3MBTL1TLR8ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 KDM4E 2584/4885NPSR1 367/4885L3MBTL1 3954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.